JW HOLDINGS CORPORATION
Financials
Valuation Metrics
JW HOLDINGS CORPORATION's Market Cap is ₩2872B. At end of 2025 it was ₩2654B. Ranked #631 of 2,405 in KR market (top 26%), #370 of 778 on KOSPI (top 48%), #67 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 287.20B KRW | KR#631/2,405 Sec#67/231 |
| Revenue | 1.01T KRW | KR#409/2,405 Sec#14/231 |
| Net Income | 156.71B KRW | KR#180/2,405 Sec#11/231 |
| Total Assets | 1.28T KRW | KR#414/2,405 Sec#20/231 |
| Net Assets | 645.69B KRW | KR#416/2,405 Sec#27/231 |
| Employees | 139 | KR#1,380/2,405 Sec#110/231 |
| Value | ||
| P/E | 1.83x | KR#71/2,405 Sec#3/231 |
| P/B | 0.44x | KR#756/2,405 Sec#29/231 |
| PEG | 0.01x | KR#129/2,405 Sec#5/231 |
| P/S | 0.28x | KR#602/2,405 Sec#14/231 |
| EV/EBITDA | 2.88x | KR#100/2,405 Sec#1/231 |
| FCF Yield | 46.76% | KR#106/2,405 Sec#1/231 |
| Profitability | ||
| ROE | 24.27% | KR#108/2,405 Sec#9/231 |
| ROA | 12.29% | KR#181/2,405 Sec#16/231 |
| Op. Margin | 18.82% | KR#184/2,405 Sec#18/231 |
| Revenue Growth | 10.18% | KR#880/2,405 Sec#85/231 |
| Earnings Growth | 161.13% | KR#290/2,405 Sec#17/231 |
| Financial Health | ||
| Debt Ratio | 97.55% | KR#1,527/2,405 Sec#174/231 |
| Total Debt | 335.32B KRW | KR#381/2,405 Sec#19/231 |
| FCF | 134.28B KRW | KR#147/2,405 Sec#7/231 |
| Cash | 75.01B KRW | KR#578/2,405 Sec#29/231 |
| Current Ratio | 0.79x | KR#1,930/2,405 Sec#189/231 |
| Net Debt/EBITDA | 1.37x | KR#772/2,405 Sec#52/231 |
| Dividend | ||
| Div. Yield | 5.42% | KR#264/2,405 Sec#7/231 |
| Div. Growth | 86.96% | KR#156/2,405 Sec#4/231 |
| Performance | ||
| 1Y Return | 19.35% | KR#337/2,405 Sec#20/231 |
| 1M Return | -9.33% | KR#1,097/2,405 Sec#103/231 |
| From 52W High | -17.69% | KR#152/2,405 Sec#7/231 |
| 1Y MDD | -19.91% | KR#55/2,405 Sec#3/231 |
| Trading | ||
| Volume | 39,379 shares | KR#1,118/2,405 Sec#115/231 |
| Trading Value | 154.1M KRW | KR#1,246/2,405 Sec#141/231 |
| Foreign Own. | 3.33% | KR#1,190/2,405 Sec#111/231 |
| Per Share | ||
| EPS | 2,120 KRW | KR#435/2,405 Sec#27/231 |
| BPS | 8,734 KRW | KR#1,086/2,405 Sec#76/231 |
Company Info
Established in 2007 as a holding company through a human spin-off of the investment and overseas business divisions from JW Pharmaceutical, the company changed its name to JW Holdings in 2010. As of the end of the current quarter, it has six subsidiaries, including JW Pharmaceutical, engaged in pharmaceutical manufacturing and sales, R&D, and medical device manufacturing and sales. Through JW Pharmaceutical, the company has entered global Phase 3 trials for the gout treatment URC102 and received clinical Phase 1 approval for the STAT3 targeted anticancer drug JW2286, driving innovative new drug development. JW Holdings is headquartered in Gwacheon, Gyeonggi-do.